Clinical trials: Rhabdoviridae Infections
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM [CNE] vaccine), made using a…
- Trial name
- NCT04062669
- Testing
- Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- Where
- 4 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years
The safety of different immunization procedures of rabies vaccine (human diploid cells) was investigated by successive design of different age groups.
- Trial name
- NCT06132789
- Testing
- Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Rabies
Immunological Tolerance After Frequent Rabies Booster Vaccinations
To study immunological tolerance effect after frequent rabies booster vaccination
- Trial name
- NCT03729102
- Testing
- Blood drawn after rabies vaccine booster vaccination
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Rabies
A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects
The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years…
- Trial name
- NCT02491541
- Testing
- Changchun Werersai, Jilin Maifeng
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza-like Illness, Upper Respiratory Disease
Non-specific Effects of Rabies Vaccine
Vaccines work by stimulating the body to produce a high-quality, rapid and specific immune response upon exposure to infection by a particular disease-causing microorganism - the microorganism targeted by the vaccine.
- Conditions
- Influenza-like Illness, Upper Respiratory Disease, Diarrhea, Fever
- Trial name
- NCT03656198
- Testing
- Rabivax-S, Sterile Water Injection
- Where
- Saint Kitts and Nevis
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Ross University School of Veterinary Medicine
Rabies
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis.
- Trial name
- MALRAB (NCT02564471)
- Testing
- Chloroquine, Atovaquone and Proguanil, Doxycycline
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Rabies, Rabies Virus
Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
This study is designed to gather safety and immunogenicity data with Purified Vero Rabies Vaccine - Serum Free (VRVg), when given in a post-exposure prophylaxis vaccination schedule, using the Essen regimen, across different…
- Trial name
- NCT01339312
- Testing
- Purified inactivated rabies vaccine, serum free, Purified Vero Rabies Vaccine
- Where
- China
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
- Trial name
- RABVAX (NCT02374814)
- Testing
- Rabies vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Rabies
Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
A four-site intradermal rabies booster vaccination in HIV - infected patients who have ever received primary rabies vaccination could improve their immune response to this kind of vaccine.
- Trial name
- NCT02547727
- Testing
- rabies vaccine
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Queen Saovabha Memorial Institute
Rabies (Healthy Volunteers)
Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.
A multicentre, open label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens (2 x 1IM regimen, 2 x 2 ID regimen, 1 x 2 ID regimen) when administering a single-dose…
- Trial name
- BAZOOKA_221 (NCT07455318)
- Testing
- Booster vaccination
- Where
- 6 sites in Belgium
- Volunteers
- 561 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Rabies
Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project
Every year, rabies, a disease transmitted to humans by rabid dogs, is estimated to kill 59,000 people globally, mostly children 15 years and below in Africa and Asia.
- Trial name
- NCT05350735
- Testing
- Intervention arm: SMS text reminders and medical card
- Where
- Kenya
- Volunteers
- 180 people
- Sponsor
- Washington State University
Rabies, Rabies Human
Survey of Human Rabies Immune Globulin Safety in Children
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States.
- Conditions
- Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
- Trial name
- NCT05382650
- Testing
- Human rabies immune globulin 300 IU/mL
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- The Methodist Hospital Research Institute
Rabies, Antibody
Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
Evaluation of immune persistence after rabies vaccination in 150 people.
- Trial name
- NCT05547815
- Testing
- 5 doses program
- Where
- China
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Changchun Zhuoyi Biological Co., Ltd
Rabies Prevention
Early Rabies Vaccine Immunization in Primary School Children
700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose of 0.1mL into the skin in the deltoid region.
- Trial name
- I49P1 (NCT01107275)
- Testing
- rabies vaccine
- Where
- Thailand
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Provincial Public Health Office, Phetchabun
Rabies
Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen
The purpose of this study is to assess the 4-site "one-week" post-exposure prophylaxis (PEP) regimen as a possible alternative to the 2-site updated Thai Red Cross (TRC) PEP regimen.
- Trial name
- NCT01622062
- Testing
- PVRV, PVRV and pERIG Favirab®
- Where
- Philippines
- Volunteers
- 600 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Virus Diseases
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
The purpose of this study is to evaluate the 1 year immunogenicity persistence of Rabipur in children 6-17 years of age, and compare the Zagreb regimen with the Essen regimen.
- Trial name
- NCT03192371
- Testing
- Rabipur
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies, Healthy Volunteers
Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults
The primary objective of this study is: To demonstrate the VRVg-2 is non-inferior to Verorab and Imovax Rabies vaccines in each age group (pediatric and adult populations) when administered as a 3-dose PrEP regimen, in terms of…
- Trial name
- VRV12 (NCT04127786)
- Testing
- Purified vero rabies vaccine - serum free - VRVg-2, Purified inactivated rabies vaccine - Verorab®, Purified inactivated rabies vaccine - Imovax® Rabies
- Where
- 4 sites in Thailand
- Volunteers
- 1,708 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
The Phase 1 clinical trial of the freeze-dried human rabies vaccine (human diploid cells) will be conducted on participants aged 10 to 60.
- Trial name
- NCT07021703
- Testing
- Freeze-dried Human Rabies Vaccine（Human Diploid Cell）, Essen, Freeze-dried Human Rabies Vaccine（Human Diploid Cell），Zagreb
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Rabies
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to <17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
- Trial name
- NCT02912845
- Testing
- KamRAB - HRIG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kamada, Ltd.
Rabies (Healthy Volunteers)
Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults
Primary Objective: To demonstrate that Purified Vero Rabies Vaccine - Serum Free Vaccine generation 2 (VRVg-2) was non-inferior to Verorab and Imovax Rabies vaccines when co-administered with human rabies immunoglobulin (HRIG)…
- Trial name
- NCT03965962
- Testing
- VRVg-2, Purified Inactivated Rabies Vaccine, Human Diploid Cell Vaccine (HDCV)
- Where
- 2 sites in France
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company